<code id='093271C5EA'></code><style id='093271C5EA'></style>
    • <acronym id='093271C5EA'></acronym>
      <center id='093271C5EA'><center id='093271C5EA'><tfoot id='093271C5EA'></tfoot></center><abbr id='093271C5EA'><dir id='093271C5EA'><tfoot id='093271C5EA'></tfoot><noframes id='093271C5EA'>

    • <optgroup id='093271C5EA'><strike id='093271C5EA'><sup id='093271C5EA'></sup></strike><code id='093271C5EA'></code></optgroup>
        1. <b id='093271C5EA'><label id='093271C5EA'><select id='093271C5EA'><dt id='093271C5EA'><span id='093271C5EA'></span></dt></select></label></b><u id='093271C5EA'></u>
          <i id='093271C5EA'><strike id='093271C5EA'><tt id='093271C5EA'><pre id='093271C5EA'></pre></tt></strike></i>

          Home / fashion / entertainment

          entertainment


          entertainment

          author:leisure time    Page View:61775
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In